

What is Claimed Is:

1. A pharmaceutical composition for a tablet comprising:
 - (a) at least one water soluble, non-fermentable cellulose derivative;
 - 5 (b) at least one lipase inhibitor in an amount effective for treating adiposity; and
 - (c) at least one excipient which is selected from an edible calcium salt; or mixtures thereof.
- 10 2. The composition according to Claim 1 wherein the water soluble, non-fermentable cellulose derivative is methylcellulose having a viscosity of > 1000 centipoise.
- 15 3. The composition according to Claim 2 wherein the edible calcium salt is dibasic calcium phosphate dihydrate, calcium phosphate anhydrous, or tribasic calcium phosphate; or mixtures thereof.
- 20 4. The composition according to Claim 3 wherein the edible calcium salt is dibasic calcium phosphate dihydrate salt.
- 20 5. The composition according to Claim 2 which further comprises a binding agent which is PVP, hydroxypropylcellulose, hydroxypropyl methylcellulose, acacia, gelatin, tragacanth, pregelatinized starch, or starch.
- 25 6. The composition according to Claim 2 which further comprises a disintegrating agent which is sodium starch glycolate, sodium carboxymethylcellulose, Ac-di-sol®, carboxymethylcellulose, veegum, alginates, agar, guar, tragacanth, locust bean, karaya, pectin, or crospovidone.
- 30 7. The composition according to Claim 2 which further comprises a wetting agent, and/or a lubricating agent.
8. The composition according to Claim 2 wherein the methylcellulose has a viscosity of >3000 centipoises.

9. The composition according to Claim 2 wherein the methylcellulose is present in an amount of about 450 to about 550mg.
10. The composition according to any of Claims 1 to 9 wherein the lipase inhibitor is orlistat.
11. The composition according to any one of Claims 1 to 9 compressed into a tablet.
12. A method for the dual treatment of adiposity and the faecal incontinence and steatorrhea associated therewith which method comprises administering to a mammal in need thereof a compressed tablet comprising:
- (a) at least one water soluble, non-fermentable cellulose derivative;
 - (b) at least one lipase inhibitor in an amount effective for treating adiposity; and
 - (c) at least one excipient which is selected from an edible calcium salt; or mixtures thereof.
13. A pharmaceutical composition for a tablet comprising:
- (a) at least one water soluble, non-fermentable cellulose derivative;
 - (b) at least one lipase inhibitor in an amount effective for treating adiposity; and
 - (c) at least one swellable diluent or filler, selected from microcrystalline cellulose, corn starch, or Starch 1500.
14. The composition according to Claim 13 wherein the water soluble, non-fermentable cellulose derivative is methylcellulose having a viscosity of > 2000 centipoise.
15. The composition according to Claim 14 which further comprises a disintegrating agent.
16. The composition according to Claim 15 which further comprises a wetting agent, and/or a lubricating agent.
17. The composition according to Claim 16 which further comprises a binding agent.

18. The composition according to Claim 14 wherein the diluent is microcrystalline cellulose and is present in a ratio of methylcellulose to microcrystalline cellulose from about 2:1 to about 14:1.
- 5
19. The composition according to Claim 14 wherein the diluent is corn starch and is present in a ratio of methylcellulose to cornstarch of from about 7.5 to about 15:1.
- 10
20. A method for the dual treatment of adiposity and the faecal incontinence and steatorrhea associated therewith which method comprises administering to a mammal in need thereof a compressed tablet comprising:
- (a) at least one water soluble, non-fermentable cellulose derivative;
- (b) at least one lipase inhibitor in an amount effective for treating adiposity; and
- 15 (c) at least one swellable diluent or filler, selected from microcrystalline cellulose, corn starch, or Starch 1500.
21. A process for preparing a tablet formulation which process comprises:
- a) blending together to form an intragranular mixture high viscosity
- 20 methylcellulose of > 3000cps; a diluent selected from microcrystalline cellulose, corn starch, or Starch 1500, or a mixture thereof, a lipase inhibitor, a lubricating agent and optionally a disintegrant; and
- b) adding to the mixture of step (a), a PVP aqueous solution, or alternatively spraying the mixture of step (a) with a PVP aqueous solution; and preparing
- 25 granulates; and
- c) blending together an extragranular mixture of a wetting agent; a lubricating agent; a diluent; and a disintegrant, or a mixture thereof; and
- d) compacting the granulates of step (b) with the extragranular mixture of step (c).
- 30
22. The process according to Claim 21 wherein the admixture of the lipase inhibitor is added in step c) rather than step a).
23. A process for the manufacture of a pharmaceutical tablet, which process
- 35 comprises mixing

- a) granulates comprising high viscosity methylcellulose of > 3000cps; at least one edible calcium salt, or mixtures thereof; a lipase inhibitor, and optionally together with an intra-granular disintegrant, and/or wetting agent, and/or colouring agent; with
- 5 b) adding to the mixture of step (a), a PVP aqueous solution, or alternatively spraying the mixture of step (a) with a PVP aqueous solution; and preparing granulates; and
- c) blending together an extragranular mixture of a wetting agent; a lubricating agent; a diluent; and a disintegrant, or a mixture thereof; and
- 10 d) compacting the granulates of step (b) with the extragranular mixture of step (c).

24. The process according to Claim 21 wherein the admixture of the lipase inhibitor is added in step c) rather than step a).